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Background: Day-hospital-based treatment programmes have been recommended for poorly functioning patients
with personality disorders (PD). However, more research is needed to confirm the cost-effectiveness of such
extensive programmes over other, presumably simpler, treatment formats.
Methods: This study compared health service costs and psychosocial functioning for PD patients randomly
allocated to either a day-hospital-based treatment programme combining individual and group psychotherapy in a
step-down format, or outpatient individual psychotherapy at a specialist practice. It included 107 PD patients, 46%
of whom had borderline PD, and 40% of whom had avoidant PD. Costs included the two treatment conditions and
additional primary and secondary in- and outpatient services. Psychosocial functioning was assessed using measures
of global (observer-rated GAF) and occupational (self-report) functioning. Repeated assessments over three years
were analysed using mixed models.
Results: The costs of step-down treatment were higher than those of outpatient treatment, but these high costs
were compensated by considerably lower costs of other health services. However, costs and clinical gains
depended on the type of PD. For borderline PD patients, cost-effectiveness did not differ by treatment condition.
Health service costs declined during the trial, and functioning improved to mild impairment levels (GAF > 60). For
avoidant PD patients, considerable adjuvant health services expanded the outpatient format. Clinical improvements
were nevertheless superior to the step-down condition.
Conclusion: Our results indicate that decisions on treatment format should differentiate between PD types. For
borderline PD patients, the costs and gains of step-down and outpatient treatment conditions did not differ. For
avoidant PD patients, the outpatient format was a better alternative, leaning, however, on costly additional health
services in the early phase of treatment.
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Personality disorders (PD) have been associated with con-
siderable social and occupational impairment, high med-
ical comorbidity, extensive health service use, and low
quality of life [1-9]. Relative to other medical and psychi-
atric conditions, the personal and economic burden of PD
is severe [10,11]. The choice of an optimal treatment for-
mat for poorly functioning PD patients has therefore high
clinical and societal relevance.
Intensive hospital-based treatment programmes, most
often day-hospital and step-down formats, are costly.
However, several studies have indicated that these treat-
ment formats yield both clinical improvements and effect-
ive prevention of suicidal crises [12-17]. The high costs of
specialized, intensive treatments may then be outweighed
by reduced emergency costs, and the programmes can be
recommended as cost-effective treatments of PD.
The day-hospital-based step-down programmes repre-
sent well-established, long-term treatment alternatives
for PD patients and are frequently found feasible [18].
Group psychotherapy is a central component of these
programmes and saves therapist resources. As patients
with different PDs are often included in the same, stand-
ard programme, the treatments are also implementable
in less populated, more rural areas.
Individual psychotherapy, provided by specialists in
outpatient practice, may be a relevant treatment alterna-
tive, presumably less intensive, and if so, also cheaper.
Clinical benefits of outpatient psychotherapy have been
demonstrated [19-21], but few have investigated the as-
sociated economic aspects and health service use. Low-
intensity outpatient treatments can be an option for
patients with milder personality pathology, but are usu-
ally considered insufficient for poorly functioning PD
patients [17,22].
Psychotherapy research has frequently focused on treat-
ments designed specifically for borderline PD, and the
cost-effectiveness of several approaches has been investi-
gated [23,24]. As yet, studies of specific treatments for
avoidant PD are scarce. There is, however, a growing con-
cern about the severity of this disorder [25-27], and in two
large cost-effectiveness studies, naturalistic patient sam-
ples in outpatient, day-hospital, or inpatient treatments
have been investigated. The first study included patients
with cluster B PDs [28], and the second, cluster C PDs
[29]. The results of these studies suggest that the cost-
effectiveness of different treatment formats differs consid-
erably for patients with different personality pathology,
favouring intensive formats for PDs within cluster C.
The present study aims, firstly, to compare costs and
clinical gains for PD patients randomly allocated to two
different formats of psychotherapy: (1) An intensive, day-
hospital-based treatment in a step-down format and (2)
individual psychotherapy in specialist outpatient practice,and secondly, to specifically investigate the differences as-
sociated with two frequent PD subgroups, borderline and
avoidant PD. The study is a part of the Ullevål Personality
Project (UPP).
Methods
The day-hospital-based step-down treatment
The step-down condition (SDC) had a maximum treat-
ment duration of four years with phases of different inten-
sity: (1) Day-hospital programme with psychodynamic and
cognitive behavioural group therapies (18 weeks), followed
by (2) outpatient therapy, with weekly conjoint individual
and group psychotherapy during the first 2.5 years and (3)
a final year of outpatient group psychotherapy alone. The
psychotherapy groups were conducted by experienced
day-hospital staff, 75% of whom had five-year group ana-
lytic training. The individual therapists were experienced,
practising psychotherapists.
The treatment in specialist outpatient practice
The treatment given in outpatient practice (OPC) had
no limitations of therapy duration, intensity, or use of
other health services. It was given in accordance with
each therapist’s preferred method and practice. The OPC
therapists were experienced, practising psychologists or
psychiatrists, and the majority reported adherence to psy-
chodynamic or psychoanalytic treatment approaches.
Participants
The study recruited naturally treatment-seeking patients
who had been referred to day-hospital treatment. Exclu-
sion criteria were based on conditions not normally
treated in day-hospital treatment: schizotypal PD, anti-
social PD, substance dependency, psychosis, organic
syndromes, bipolar I, untreated attention-deficit hyper-
activity, or pervasive developmental disorder. Patients
were assessed before random assignment to SDC or
OPC. An independent randomization co-ordinator was
responsible for randomization procedures (computer-
generated random numbers, Statistical Package for the
Social Sciences, SPSS) [30]. Additional file 1: Chart 1
demonstrates the numbers of patients who were ex-
cluded, who withdrew, or who missed assessments. Stat-
istical analyses included a total of 107 patients (nSDC =
56 and nOPC =51). Mean age of this sample was 31 years
(SD = 7), and 76% of the patients were female.
Baseline diagnostic assessments
Standardised, semi-structured diagnostic interviews for
Axis-I and -II disorders were conducted before random-
isation: (1) the Mini-International Neuropsychiatric Inter-
view (M.I.N.I.) version 4.4 for Axis-I diagnoses [31]; and
(2) the Structured Clinical Interview for DSM Disorders
(SCID-II) for Axis-II diagnoses [32]. Clinical day-hospital
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interviews. The reliability of Axis-II diagnoses was con-
firmed by an independent observer who rated 24 video-
taped SCID-II interviews. The kappa values for avoidant
and borderline PD were 0.75 and 0.66, respectively.
Table 1 shows baseline Axis-I and -II diagnoses for the
107 patients included in longitudinal analyses.Assessments of health-service use
Information on health-service use and medication was
collected through UPP-designed interviews and ques-
tionnaires. Reports of health-service use included (1)
psychotherapeutic treatment (outpatient clinic, practis-
ing specialist, and psychotherapeutic day hospital), (2)Table 1 Axis-I and -II disorders at baseline
SDC (n = 56) OPC (n = 51)
Axis-II disorders Number (%) Number (%)
Most frequent
Borderline 27 (47) 24 (46)
Avoidant 26 (45) 18 (35)
Comorbidity
Borderline and Avoidant 10 (17) 6 (12)
Borderline, not Avoidant 17 (33) 18 (35)
Avoidant, not Borderline 16 (31) 12 (22)
Other Axis-II disorders
Schizoid 1 (2) 0
Paranoid 10 (17) 6 (12)
Narcissistic 0 2 (4)
Obsessive-compulsive 7 (12) 3 (6)
Dependent 4 (7) 3 (6)
Axis-II not otherwise specified 10 (17) 13 (25)
Axis-I disorders
Mood 49 (85) 46 (89)
Anxiety 52 (90) 44 (85)
Obsessive-compulsive 9 (16) 4 (8)
Somatoform 6 (10) 5 (10)
Eating 6 (10) 9 (17)
Substance abuse/dependency 11 (19) 17 (33)
Post-traumatic stress disorder 5 (9) 5 (10)
Severity of the disorder Mean (SD) Mean (SD)
Number of Axis-I disorders 3.5 (1.4) 3.3 (1.5)
Number of Axis-II disorders 1.5 (0.7) 1.3 (0.6)
Number of Axis-II criteria 14.9 (6.3) 14.8 (5)
Quality of life 3.3 (1.6) 3.6 (1.7)
Symptom distress (SCL-90-R, global index) 1.7 (0.7) 1.8 (0.5)
Interpersonal problems (CIP) 1.7 (0.5) 1.7 (0.5)
Standard deviation (SD). Step-down condition: SDC, Outpatient condition: OPC.emergency health services (psychiatric and general out-
patient emergency services, admissions to psychiatric
and medical hospitals, emergency outpatient and in-
patient treatment at mental health centres and addiction
clinics), (3) general practitioner (GP) visits, (4) commu-
nity services (psychiatric community nurse, community
day centre, and social welfare co-ordinator visits), (5)
other specialist services (outpatient, day-patient or in-
patient treatment at an addiction clinic or day-patient
treatment at a psychiatric hospital), and (6) pharmaco-
logical treatment. The sum of health services included
those listed in points 1–6.
Use of health services and medication was reported
retrospectively for four time periods: The year preceding
randomisation (period 0), the initial 0–8 months of the
trial (period 1), the middle 9–18 months (period 2), and
the final 19–36 months (period 3). Table 2 demonstrates
the frequencies of different health services used.
Estimation of health service costs
Calculations of mean monthly costs were based on the
individual patients’ reported health service use in each
assessment period and the standard costs of each spe-
cific service. Standard costs of day-hospital treatment
were estimated using annual accounts from the Depart-
ment of Personality Psychiatry, Oslo University Hospital.
Costs per outpatient consultation in OPC and SDC were
based on reports of annual activity and income for the
participating therapists. Costs related to treatment at
mental health centres, medical and psychiatric hospitals,
addiction clinics, outpatient general and psychiatric
emergency services, and GPs were obtained from pub-
lished reports [33-36]. Costs related to community and
social services were based on information from one large
municipality. Medication costs were based on informa-
tion from the Norwegian Medicines Agency. All unit
costs are from the year 2006 and are presented in euros
(Table 3). The exchange rate was 1 euro = 8 Norwegian
krone (NOK). Table 4 demonstrates the mean monthly
sum of health service costs per patient for each assess-
ment period.
Assessments of functioning
Global functioning (GAF; Axis V, DSM-IV, American
Psychiatric Association) was evaluated at the baseline as-
sessment and at all follow-up assessments (after 8, 18,
and 36 months). The observer-rated GAF provides a
composite score of psychosocial functioning on a 0–100
scale. Higher GAF scores indicate better psychosocial
functioning, and a level of 60 represents the cut-off
point between satisfactory functioning/mild impairment
and moderate/severe impairment. Baseline GAF was
rated by day-hospital staff [37], and ratings at 8-, 18-,
and 36-month time points were performed by research
Table 2 Health-service use and occupational functioning
The year before the trial First 0–8 months of trial Last 19–36 months of trial
% full sample % OPC % SDC % OPC % SDC
All PDs APD BPD All PDs APD BPD All PDs APD BPD All PDs APD BPD All PDs APD BPD
Psychotherapy
Outpatient clinic 58 56 76 44 50 47 56 50 59 20 0 27 82 92 79
Practising specialist 25 28 16 80 90 71 56 64 47 54 75 40 36 50 36
Psychotherapeutic day hospital 6 8 8 17 30 12 98 100 94 0 0 0 0 0 0
Emergency services
Emergency outpatient services 41 28 56 28 10 24 21 21 18 37 25 40 34 8 50
Psychiatric inpatient services 24 24 36 17 20 12 12 14 12 6 0 7 16 17 7
Medical inpatient services 17 8 28 11 0 18 12 7 18 23 25 20 11 8 14
GP and community services
General practitioner 90 84 92 79 75 78 78 63 94 97 100 93 91 75 93
Community healthcare/social services 35 20 56 54 70 47 42 43 35 54 63 53 71 67 79
Social welfare coordinator 28 14 44 49 57 35 39 43 29 53 70 53 55 35 71
Other specialist services
Addiction clinic, outpatient 9 8 12 13 20 12 0 0 0 0 0 0 5 8 7
Psychiatric hospital, day patient 14 12 20 2 7 0 0 0 0 0 0 0 2 0 7
Pharmacological treatment 61 56 68 64 70 59 64 71 71 33 37 33 50 42 54
Start of the trial 8-month assessment 36-month assessment
% full sample % OPC % SDC % OPC % SDC
All PDs APD BPD All PDs APD BPD All PDs APD BPD All PDs APD BPD All PDs APD BPD
Occupational functioning
Present employment/education 49 40 59 58 50 81 49 50 50 80 87 70 61 58 70
Health-service use and occupational functioning (%) is presented for the full sample (all PDs), and for subgroups of PD patients with avoidant (APD), and not comorbid borderline (BPD), and BPD, not APD during
period 0 (the year before randomisation), period 1 (the first eight months of the trial), and period 3 (the last 19–36 months of the trial).
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Table 3 Standard costs of health services
Cost per consultation/day €
Psychotherapy
Outpatient clinic 118
Practising specialist 110
Psychotherapeutic day hospital 165
Emergency services
Emergency outpatient services 101
Psychiatric inpatient services 644
Medical inpatient services 1077
Psychiatric hospital, day patient 445
GP
General practitioner 33
Community services
Community healthcare/social services 48
Social welfare coordinator 28
Mental health centre, day patient 309
Addiction treatment
Addiction clinic, outpatient 118
Addiction clinic, day patient 309
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raters. The reliabilities (ICC (2,1): intra-class correlation
coefficients, two-way, single, random measures) for GAF
scores were 0.56 at baseline (confidence interval, CI:
0.02–0.83), 0.81 at 8 months (CI: 0.51–0.92), 0.85 at 18
months (CI: 0.59–0.94), and 0.94 at 36 months (CI:
0.88–0.97). Table 4 shows mean GAF scores at all as-
sessments. Occupational status was assessed using a
questionnaire designed for UPP.
Completeness of data
The average number of assessments per patient over the
study period was 3.3 (SD = 0.9), with equal frequencies inTable 4 Mean costs and psychosocial functioning
Step-down condition
Costs
n Mean (SD) Median
Costs: The year before trial 45 844 (1793) 160
GAF: 0 months
Costs: First 0–8-month period 52 1462 (854) 1325
GAF: 8 months
Costs: 9–18-month period 47 618 (806) 496
GAF: 18 months
Costs: Last 19–36-month period 45 794 (1128) 474
GAF: 36 months
The table demonstrates mean monthly costs (€) per patient (treatment and additio
scores at baseline (0) and after 8, 18, and 36 months. Statistically significant differen
asterisk (* = P < 0.05, independent-samples t-tests).SDC and OPC. Fifty-four percent of the patients (n = 59)
responded at all four assessments (OPC= 57%, SDC=
50%), while 26% (n = 29) were assessed three times (OPC =
15%, SDC = 36%), and 15% (n = 16) were assessed twice
(OPC= 24%, SDC = 7%). One patient in OPC and two in
SDC had only one assessment.
Informed consent
The UPP was approved by the Norwegian Data Inspect-
orate and the Regional Committee for Medical Research
Ethics. Participation was obtained with written informed
consent.
Statistical procedures
Longitudinal data were statistically analysed by mixed
models (SPSS, version 19). Model fit was decided by
comparing log likelihood statistics (Aikikes Information
Criterion, AIC).
A piecewise change model [38] combining periods 0–1
(linear curves) and periods 1–3 (linear or quadratic curves)
with a knot at period 1 gave the best approximation to the
data. For periods 1–3, quadratic curves were chosen to
model the longitudinal change of the health service cost
variables: treatment, emergency services, and the sum of
all health service costs, while linear curves were chosen for
the other cost variables and GAF scores. In addition, a lin-
ear change model included only periods 0 and 3. Unstruc-
tured covariance was chosen for the repeated measures.
Such covariance minimizes the risk for type I errors [39]
and gave the best model fit.
The main predictor analyses investigated the longitu-
dinal effect of treatment condition on health service costs
and global functioning. The effects of the diagnostic vari-
ables were investigated as predictors and as moderators.
The main moderator analyses included the baseline inter-
actions: treatment condition × PD (thus controlling for
baseline variation) and the three-way interaction withOutpatient condition
GAF Costs GAF
Mean (SD) n Mean (SD) Median Mean (SD)
47 (4) 46 1406 (2604) 370 48 (5)
51 (10) 46 1294 (3034) 536 50 (12)
53 (10) 37 944 (1771) 368 57 (12)
57 (12)* 36 407 (620) 270 67 (13)*
nal health services) for each assessment period and global functioning (GAF)
ces between the outpatient and step-down condition are marked with an
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analyses included models testing the possible effects of co-
morbidity with other Axis-I or -II disorders.
In this study, 16 patients had both borderline and
avoidant PD, leaving 28 and 35 patients with avoidant or
borderline PD, respectively. However, all statistical infer-
ences in the moderator analyses are based on models in-
cluding all patients (n = 107), models with patients who
had at least three assessments (n = 88), and models con-
trolling for the separate effects of comorbidity.
Table 5 shows estimates of differences in the longitu-
dinal course of costs: (A) treatment, (B) emergency
services, and (C) the sum of health service costs for pa-
tients in the two treatment conditions and subgroups
with borderline and avoidant PD. Table 6, section A,
demonstrates differences in the longitudinal course of
GAF. Mixed-model analyses of the other variables are
described in the results section with the correspondingTable 5 Estimated differences in costs for patients in step-do
Δ costs: first trial
period (0–8months)
Δ chang
Δ mean
estimate (SE)
P Δ initial
slope (SE)
Costs per patient
(A) Monthly costs
of treatment
Δ (SDC-OPC) 720 (69) .00 −86 (7)
Predictor effects within
OPC
Δ (APD - other PDs) 264 (101) .01 −19 (12)
Δ (BPD - other PDs) −11 (101) ns −8 (11)
(B) Monthly costs
of emergency
services
Δ (SDC-OPC) −797 (500) ns 45 (64)
Moderator effects
Δ (SDCAPD - OPCAPD) −2411 (829) .005 179 (109)
Δ (SDCBPD - OPCBPD) −1451 (749) ns 199 (95)
(C) Sum of all
monthly costs
Δ (SDC-OPC) 10 (504) ns −53 (65)
Moderator effects
Δ (SDCAPD - OPCAPD) −1717 (829) .04 92 (109)
Δ (SDCBPD - OPCBPD) −639 (755) ns 94 (96)
(D) Sum of all
costs over 36
months
All patients
Moderator effects
Predicted change:
APD (not BPD)
Predicted change:
BPD (not APD)
Table 5 shows mixed-model estimates of (A) treatment, (B) emergency, and (C) tota
(SDC: the step-down condition, OPC: the outpatient condition). Monthly costs in the
means for the whole trial period are presented as: (1) Δ (SDC-OPC): Differences (Δ) b
subgroups within OPC. (3) Moderator effects: Cost differences between SDC and OP
(b) borderline PD, BPD: Δ (SDCBPD - OPCBPD). Estimates are presented as means with
fit for each model. Table 5 also shows (D): The sum of all costs over 36 months: Estim
difference) based on mixed-model predicted values for all patients and subgroups
indicates p > 0.05.P-values denoted by PPWM (piecewise model) and PLM
(linear model for period 0–3). Independent-samples t-
tests were used for other comparisons, and when refer-
ring to these analyses, P-values are denoted by PTT.Possible bias of missing data
It is recommended to investigate the possible bias from
missing data by comparing subsamples of patients with
different attrition patterns using mixed-model statistics
[40]. The piecewise change model was therefore used to
compare trajectories for: (1) patients with and without
the last assessment (n = 81) and (2) patients with all four,
three, and two assessments. Longitudinal change for the
investigated subgroups did not differ significantly from
the rest of the sample (all differences P > 0.05). More-
over, comparison of log likelihood statistics and residual
variation indicated that the subsamples did not representwn and outpatient treatment
e in costs per month
during trial
Δ costs: entire trial
period (36 months)
Model fit
P Δ curvature
(SE)
P Δ grand
mean (SE)
P AIC
.00 2 (0.2) .00 281 (33) .00 4814
ns 0.4 (0.3) ns 136 (43) .00 4813
ns 0.2 (0.3) ns 61 (41) ns 4819
ns −0.4 (1.9) ns −331 (28) .00 5541
ns −3.4 (3.3) ns −956 (120) .00 5547
.04 −4.9 (2.8) ns −303 (86) .00 5546
ns 2 (2) ns 7 (44) ns 5625
ns −1.3 (3.5) ns −905 (147) .00 5626
ns −2.1 (3.0) ns −37 (88) ns 5632
Mean estimate (SE) Incremental
costs (SE)SDC OPC
31823 (479) 31607 (956) ns
35524 (381) 49728 (525) .00 −14204 (633)
29709 (1275) 21309 (2482) ns
l (all health service) costs (€) in models with treatment included as a predictor
first trial period, change per month for the 0–36 month trial period, and grand
etween SDC and OPC. (2) Predictor effects within OPC: Cost differences for
C for subgroups of patients with (a) avoidant PD, APD: Δ (SDCAPD - OPCAPD) and
standard errors (SE). Akaikes Information Criterion (AIC) indicates goodness of
ations of total 36-month costs and incremental costs (if significant SDC-OPC
with (a) avoidant and (b) borderline PD. P-values are presented if p < 0.05, ns
Table 6 Estimated differences in clinical gains for patients in step-down and outpatient treatment
Δ GAF at 0 months Δ GAF-change rate per month
during trial
Model fit
Δ mean estimate (SE) P Δ Slope (SE) P AIC
(A) Global functioning (GAF) Δ (SDC-OPC) 1.3 (2.1) ns −0.4 (0.1) .00 2586
Moderator effects
Δ (SDCAPD - OPCAPD) 1.6 (3) ns −0.5 (0.2) .00 2583
Δ (SDCBPD - OPCBPD) 0.6 (3) ns −0.3 (0.2) ns 2594
(B) 36-month GAF change Δ GAF (0-36-months) mean estimates (SE) Incremental effects (SE)
SDC OPC
All patients 10 (0.3) 18 (0.1) .00 −8 (0.3)
Moderator effects
Predicted change: APD (not BPD) 6 (0.5) 19 (0.01) .00 −13 (1)
Predicted change: BPD (not APD) 14 (0.6) 17 (0.2) ns
Table 6 shows mixed-model estimates of the Global Assessment of Functioning (GAF) in models with treatment included as a predictor (SDC: the step-down
condition, OPC: the outpatient condition). (A): Mean estimated GAF (SE: standard error) at baseline (intercept) and change per month (linear slope) during the trial
presented as (1) Δ (SDC-OPC): Difference (Δ) between SDC and OPC, and (2) Moderator effects: (SDC-OPC) difference for subgroups of patients with (a) avoidant
PD, APD: Δ (SDCAPD - OPCAPD) and (b) borderline PD, BPD: Δ (SDCBPD - OPCBPD). Akaikes Information Criterion (AIC) indicates goodness of fit for each model.
(B): 36-month GAF change: Estimations of 36-month GAF change and incremental effects (when a significant difference existed between SDC and OPC) based on
mixed-model predicted values. P-values are presented if p < 0.05, ns indicates p > 0.05.
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therefore concluded that the bias was small.
Extreme costs
The results of cost analyses were cross-checked in sam-
ples, excluding six patients (n = 101) with extreme cost
values. These outliers included one OPC patient (avoi-
dant PD) with high emergency costs because of exten-
sive psychiatric hospitalisation and five patients with
more than seven days of medical hospitalisation (four
OPC patients: two with avoidant PD, two with border-
line PD, and one SDC patient with borderline PD).
Incremental costs and effects
The incremental cost per patient was defined as the differ-
ence in the sum of all health service costs over the whole
36-month trial period for SDC patients versus OPC pa-
tients (Table 5, section D). The incremental effect was de-
fined as the difference in GAF improvement for SDC
versus that of OPC over the same period (Table 6, section
B). Calculations of both were based on mixed-models pre-
dicted values. The incremental cost per incremental effect
indicates the extra cost per GAF point gained.
Results
Costs of the two specialist treatments
Hospital-based, step-down treatment (SDC) was, in it-
self, more expensive than psychotherapy in specialist
outpatient practice (OPC) (Table 5 section A). Initial
day-hospital treatment in SDC (period 1) was the most
costly (Figure 1). Although the shift from day-hospital
to outpatient conjoint therapy (period 1 to period 2)
represented a sharp cost decline, average monthly costsnevertheless remained higher than OPC throughout the
trial.
In SDC, there was generally little variation in treat-
ment costs and no significant deviation related to any
PD subgroups (PPWM > 0.1). In OPC, treatment costs
varied more, and depended on the patient’s type of PD.
For patients with avoidant PD, treatment costs were es-
pecially high in period 1 (Table 5, section A). Compared
with other OPC patients, these patients reported more
frequent individual therapy sessions [meanAPD 21 (SD
13) versus meanother PDs 15 (SD 15), PTT < 0.05] and a
greater number of additional consultations at outpatient
clinics, other day-hospital treatment, and addiction
treatment (all PTT < 0.05). Treatment costs in SDC and
OPC were not influenced by comorbid mood or anxiety
disorders, other specific PDs, or increasing numbers of
Axis-I or -II disorders (PPWM > 0.1).
Additional health service costs during the trial
Emergency health service costs during the trial
Average monthly emergency costs over the trial period
were generally higher in OPC than in SDC (Table 5, sec-
tion B, grand means, and Figure 1). There was an overall
emergency cost decline from baseline to 36 months in
both treatment conditions (period 0–3: no significant
difference, PLM > 0.1), and a significant trend of more
rapid initial cost reductions for borderline PD patients
in SDC (Table 5, section B).
OPC patients with avoidant PD were associated with
particularly high emergency service costs in period 1
(Table 5, section B and Figure 1) with more frequent
use of inpatient psychiatric services (Table 2) and a
higher number of inpatient days [mean number of days:
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Figure 1 Longitudinal change of health service costs and global functioning. The figures illustrate the longitudinal course (mixed-model
estimations) of health service costs (mean total health service costs: solid black line, mean treatment costs: blue dotted line, and mean
emergency costs: red dotted line) with costs (in euros) given on the left Y-axis. The change trajectory for global functioning (given on the right
Y-axis) is represented by the black dotted line. Separate figures demonstrate (1) the full sample of patients with different personality disorders
(mixed PD) in the step-down (SDC) and the outpatient condition (OPC), (2) patients with borderline PD (BPD), and (3) with avoidant PD (APD) in
the two treatment conditions. The point of randomisation is denoted by Time = 0 months.
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(PTT < 0.05)]. The trend persisted in the model that ex-
cluded extreme outliers [mean number of days, OPC:
5 (SD 17)].
Increasing numbers of PDs were also associated with
higher emergency costs in OPC [mean cost increase
(euros) per PD: 910 (SE 328), PPWM = 0.007]. In SDC
neither PD subgroups nor increasing numbers of PDs
were associated with deviating emergency costs duringthe trial (PPWM >0.1). In both SDC and OPC, emergency
costs were not significantly influenced by differences in
Axis-I comorbidity (numbers of Axis-I disorders, or spe-
cific mood or anxiety disorders, PPWM > 0.1).
Medication, GP, and community service costs during the
trial
The average monthly costs of medication were higher
in OPC than in SDC in period 1 (PPWM < 0.05), but
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between treatment conditions (PPWM > 0.1). Costs of
GP consultations declined over time in both SDC and
OPC (PPWM > 0.01). Costs of community-based ser-
vices were initially low, increased over time (PPWM
< 0.05), and did not differ between treatment conditions
(PPWM > 0.1). Avoidant PD patients in OPC reported
greater use of community health services relative to
other PDs (PTT < 0.05). Medication, GP, and community
services costs were not influenced by Axis-I comor-
bidity (PPWM > 0.1).The sum of costs and clinical gains over the trial period
The sum of health service costs (trial treatment and all
additional health services) for each month and for the
full 36-month trial period did not differ by treatment
condition, and costs declined over time in both condi-
tions (Table 5, section C, D, and Figure 1). Clinical gains
were superior in OPC after 36 months (Table 6, section
A, B, and Figure 1). However, investigations of the two
major PD subgroups revealed considerable differences
within the sample.
Cost differences were insignificant for borderline PD pa-
tients (Table 5, section C and D). Clinical improvement
was found in both treatment conditions (Table 6, section A
and B). At the final assessment (period 3), GAF scores were
within mild impairment levels [mean GAFborderlineOPC: 65
(SD 2), mean GAFborderlineSDC: 61 (SD 6), PTT > 0.05]. In
both treatment conditions, 70% reported employment or
study by 36 months (Table 2). The increase in the propor-
tion employed or studying from baseline to 36 months was
16%.
Health service costs were considerably higher for
avoidant PD patients in OPC, but clinical outcomes
were also better (Figure 1). This was demonstrated by
higher monthly health service costs over the full trial
period and especially during period 1 (Table 5, section
C), along with GAF improvements in the last phase of
the trial (Table 6, section A). Non-clinical GAF levels
were reached only in OPC [Period 3: mean GAFavoidantOPC:
66 (SD 0.1); mean GAFavoidantSDC: 53 (SD 3), PTT < 0.05],
and occupational status was also better for OPC patients
at 36 months (Table 2). There was a 54% increase (base-
line to 36 months) in the proportion of avoidant PD pa-
tients who were employed or studying in OPC. The
corresponding increase in SDC was 31%. SDC was
cheaper, but less effective, and the extra cost for each
additional GAF point gained per avoidant PD patient in
OPC would be 1092 euros (incremental cost per incre-
mental effect).
Health service costs and GAF were not influenced by
comorbidity of other specific PDs or other Axis-I or -II
disorders (PPWM > 0.1).Health service costs and functioning the year before the
trial
In the year before the trial, the average monthly costs of
all health services did not differ by treatment condition
(PLM > 0.1). These baseline assessments revealed high
costs of health services, poor global functioning, consid-
erable comorbidity, symptom distress, and interpersonal
problems (Figure 1, Tables 1 and 4). Compared with the
rest of the sample, borderline PD was associated with
particularly high costs of emergency services [mean cost
difference: euros 955 (SE 441), PLM = 0.03]. Avoidant PD
was associated with poorer global functioning [mean
GAF difference: -2(SE 1), PLM = 0.03], but there was no
indication of extreme health service use before the trial.
Neither comorbid mood or anxiety disorders, other spe-
cific PDs nor increasing extent of Axis-I or -II comor-
bidity had significant influence on health service costs or
functioning (both PLM >0.1).
Discussion
Our main findings were:
1) The step-down format required little adjuvant health
services and was therefore not the more expensive,
but its clinical effectiveness depended on type of PD
pathology.
2) There was no difference in the cost-effectiveness of
step-down and outpatient treatment for patients
with borderline PD.
3) Outpatient treatment was clinically effective for
avoidant PD patients, but also the most costly for
this PD subsample, owing to considerable adjuvant
health services.
Step-down treatment is recommendable for treatment of
borderline PD
Before starting treatment, borderline PD patients had
the highest emergency costs in the sample. This observa-
tion reflects the well-described trend of extensive health
service use previously associated with borderline PD [6].
In the course of the trial, the cost effectiveness of the
two treatments could not be distinguished. Similarly, a
cost-effectiveness study from the Netherlands found
both day-hospital and outpatient formats recommend-
able in treatment of cluster B disorders [28]. Our study
suggests a greater potential for specialist outpatient
treatments for borderline PD patients than might have
been expected, but additionally, it confirms that such
treatments do not necessarily have lower overall costs
when all services are included. The step-down condition
had comparable costs and represented a well-defined
treatment in its own right with little need for adjuvant
health services. The latter are obvious advantages for
both the patient and healthcare provider.
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Clinical effectiveness after 36 months was generally good
in the outpatient condition. Costs, however, were highly
variable. The composition of treatment and adjuvant
health-service resources depended on the outpatient ther-
apist’s evaluation of the patient, and presumably, also on
personal style, interest, and availability. This flexibility had
remarkable consequences for patients with avoidant PD.
Avoidant PD patients characteristically reported low
functioning, but moderate use of health services the year
before the trial. Their health service costs early in the
trial therefore represent a considerable cost expansion
reflecting a broad range of health services, both “high-”
and “low-cost” services. Costs remained higher than the
rest of the sample throughout the trial, although they de-
clined together with clinical improvements in later phases.
We have not found any other studies that report health-
service use among avoidant PD patients. In the previously
mentioned cost-effectiveness study of cluster C PDs [29],
the most intensive treatment formats (day-hospital and in-
patient treatment) were more cost-effective than out-
patient treatment. In light of the adjuvant health services,
the contrast to our outpatient condition may not be so
great. However, our results are based on a small sample,
and their generalisability is therefore uncertain. We never-
theless find the expansion of health service costs note-
worthy, as the trend was still evident in analyses excluding
patients with extreme emergency costs.
Were the “additional benefits” of the more effective out-
patient treatment worth the “additional cost” for avoidant
PD patients? From an economic perspective, one may say
that if the high costs or extra health services “invested” in
the outpatient condition contributed to superior long-
term clinical gains, the extra costs per GAF point gained
from outpatient treatment, for each patient with avoidant
PD, would be 1092 euros [41]. The societal costs of one
year of disability would, by far, exceed the extra costs in
the outpatient condition. It is therefore likely that the out-
patient treatment would have been the more cost-effective
if we had also included societal costs. However, we cannot
say for certain that the costs invested had any relation to
the later improvements. The observed overall intensifica-
tion of health care use in the outpatient condition may
reflect a psychological destabilisation among vulnerable
avoidant PD patients. Final outcomes would then depend
upon how this destabilisation was managed. One could
speculate that the flexibility of the format in itself was an
important clinical factor. An integrated and eclectic treat-
ment approach closely attuned to the individual has in-
deed been promoted in the treatment of severe PD [42].
The present study, however, has not included data on
treatment processes.
We conclude that the long-term clinical effectiveness of
outpatient treatment was impressive. However, because ofthe small sample size and the complexity and variation of
adjuvant health services, we cannot identify specific com-
ponents of the outpatient condition recommendable for
the treatment of avoidant PD.The step-down programme
In the step-down condition, costs were remarkably
homogenous, independent of the patient’s type of PD or
other comorbid Axis-I or -II disorders. Our trial clearly
demonstrates how the expectedly, high costs of step-
down treatment were offset by the considerably lower
costs of additional health services. Emergency services
were equally available for patients in the two comparison
treatments. In a study of health service use costs, Chiesa
et al. similarly demonstrated that reduced emergency
costs gave overall cost savings for expensive, clinically ef-
fective, hospital-based PD treatment programmes over
less specified, non-specialist psychiatric treatment [14].
In the present study, the question of cost-effectiveness is
more complicated for patients with avoidant PD. The less
costly step-down alternative had also the least effect.
Emergency services are expensive and reflect severe
clinical hazards. It could be assumed that step-down treat-
ment prevented emergencies, and in itself, this would be
an important benefit. However, we found that the use of
cheaper outpatient emergency services in period 1 was
actually more frequent in the step-down condition, which
could suggest that avoidant PD patients in step-down
treatment also experienced insufficient psychological con-
tainment in the first phase of treatment. The dismaying
results of step-down treatment for avoidant PD patients
are based on a small sample. However, in recent five-year
follow-up studies of large PD cohorts (n = 352 and n =
790), poor long-term functioning and prevailing symptom
distress were demonstrated for avoidant PD patients after
similar step-down treatment [27,43]. Thus, the traditional
step-down approaches may not be cost-effective for pa-
tients with avoidant PD.
Our results highlight a need for further investigation
of the therapeutic process for individuals with avoidant
personality structures. Several recent studies have focused
on therapist style, interventions, and treatment principles
in individual therapy for these patients [25,44-49]. We
have not found process studies from intensive step-down
treatments or outpatient group psychotherapy. More pro-
found investigations, including case studies or qualitative
interviews, might provide a better understanding of ele-
ments of the step-down treatment or group psychotherapy
in need of modification, or of elements of the outpatient
format that are beneficial. One hypothesis is that the type
of step-down treatment investigated in this study is too
supportive for avoidant PD patients. Embedded in a Scan-
dinavian welfare state, it might be that patients are not
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behaviour also within the treatment programme.Strengths and limitations
The UPP project aimed to recruit individuals from a
naturally treatment seeking population of poorly func-
tioning PD patients. We found that the baseline levels of
functioning and distribution of diagnoses described in
this study were similar to those described in other natur-
alistic, clinical studies of PD patients in day-hospital,
step-down, and inpatient treatments [27,50], thus indi-
cating that the present study population is clinically
representative.
In clinical PD research, attrition is a frequent problem.
This was also the case in our study. The lowest response
rate was at the last assessment, with 25% of patients
missing. Mixed-model statistics are a recommended stat-
istical method for analyses of longitudinal data with long
follow-up periods, uneven time intervals, and unequal
numbers at each assessment [38]. Individual change tra-
jectories are based on all available data. In our study, the
longitudinal analyses thus incorporate all 107 patients.
In the Methods section, we elaborated on our investiga-
tions concerning the possible bias of missing data. Al-
though attrition will always represent some uncertainty,
we conclude that it did not cause any systematic bias in
the present study.
The validity of the statistical model (how well the
change model describes the actual change pattern in the
data) is an important limitation. Modelling procedures
in the present study are described in the subsection
about statistics. We found that correlations between the
mixed models’ predicted values and the samples’ mean
values were all significant (P < 0.01), an indication of sat-
isfactory validity.
Registration of health-service use was based on patient
interviews, and could be biased by the quality of pa-
tients’ recollection. The accuracy of reported frequencies
of GP consultations, use of other community services,
and medications may have suffered. However, important
differences were associated with the use of emergency
services. It can be argued that the more exceptional and
dramatic nature of such situations likely increases the
probability that they were reported accurately.
It should also be emphasised that the “costs” in the
present study included only health services and not so-
cietal costs, such as loss of productivity. Societal costs
are likely to be high among poorly functioning patients.
For avoidant PD patients in the present trial, the de-
crease of unemployment and disability was considerably
greater in the outpatient than the step-down condition.
A broader cost analysis that included societal costs
would most likely have strengthened the present resultsof our study by demonstrating greater cost savings in
the outpatient condition.
The use of observer-rated GAF as a measure of clinical
outcomes can be a limitation. Evaluations before ran-
domisation were performed by day-hospital staff. Later
evaluations were performed by research fellows and cross-
checked by a second evaluator. Although GAF reliability
was low at baseline, it was high during later periods, and
very high in the last period, where we also found signifi-
cant differences between the treatment conditions. Unreli-
able GAF ratings were therefore not likely to have biased
these results. Moreover, the second clinical outcome
measure, the self-report of occupational functioning, cor-
responded well with the GAF results.
Conclusion
This study highlights the importance of cost-effectiveness
studies in the treatment of PDs. We found no significant
difference of costs for efficient treatment of borderline PD
in two different treatment formats. Patients with avoidant
PD improved more in the outpatient format, although it
was more costly in the initial phase due to high supple-
mentary medical and mental health service costs.
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